Her primary areas of study are Genetics, Breast cancer, Mutation, Cancer and Germline mutation. Genetics is often connected to Large series in her work. Her biological study spans a wide range of topics, including Gene mutation, Cancer research and Single-nucleotide polymorphism, Genotype.
Her study in Genotype is interdisciplinary in nature, drawing from both Ovarian cancer and Allele. Her Mutation research is multidisciplinary, relying on both Genetic testing and Exon. Her work deals with themes such as Gene rearrangement and Coding region, which intersect with Frameshift mutation.
Sylvie Mazoyer mainly investigates Genetics, Breast cancer, Gene, Ovarian cancer and Cancer research. Her study in Exon, Mutation, Allele, Germline mutation and Locus is carried out as part of her studies in Genetics. She combines subjects such as Gene rearrangement and Genetic testing with her study of Mutation.
Her Breast cancer research includes elements of Genome-wide association study, Genotype, Single-nucleotide polymorphism and Oncology. Her studies deal with areas such as Gene mutation and Haplotype as well as Single-nucleotide polymorphism. In her research, Nonsense-mediated decay is intimately related to Molecular biology, which falls under the overarching field of Gene.
Her primary scientific interests are in Genetics, Breast cancer, Genome-wide association study, Ovarian cancer and Oncology. Her Locus, Allele, Gene, Single-nucleotide polymorphism and Genetic association investigations are all subjects of Genetics research. In Locus, Sylvie Mazoyer works on issues like Genotype, which are connected to Cancer research.
Her research in Breast cancer intersects with topics in Mutation, Germline mutation and Genetic testing. Her study in the fields of BRCA2 Mutation under the domain of Ovarian cancer overlaps with other disciplines such as Medical research. Sylvie Mazoyer has researched Oncology in several fields, including Pancreatic cancer, Genetic predisposition, Internal medicine, Case-control study and Prostate cancer.
Breast cancer, Genome-wide association study, Genetics, Internal medicine and Oncology are her primary areas of study. Her Breast cancer study incorporates themes from Mutation, Cancer research, Risk factor and Medical genetics. The various areas that Sylvie Mazoyer examines in her Mutation study include Cancer, Exon skipping and FANCM.
The Cancer research study combines topics in areas such as Genotyping, Serous fluid, Allele and Age of onset. Her Risk factor research includes themes of Single-nucleotide polymorphism and Gene mutation. Sylvie Mazoyer is studying Locus, which is a component of Genetics.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation.
S. A. Gayther;W. Warren;S. Mazoyer;P. A. Russell.
Nature Genetics (1995)
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer
Stig E. Bojesen;Stig E. Bojesen;Karen A. Pooley;Sharon E. Johnatty;Jonathan Beesley.
Nature Genetics (2013)
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.
Timothy R. Rebbeck;Nandita Mitra;Fei Wan;Olga M. Sinilnikova.
JAMA (2015)
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population
Antonis C. Antoniou;Xianshu Wang;Zachary S. Fredericksen;Lesley McGuffog.
Nature Genetics (2010)
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers
Antonis C. Antoniou;Antonis C. Antoniou;Amanda B. Spurdle;Amanda B. Spurdle;Olga M. Sinilnikova;Olga M. Sinilnikova;Sue Healey;Sue Healey.
American Journal of Human Genetics (2008)
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk
Fergus J. Couch;Xianshu Wang;Lesley McGuffog;Andrew Lee.
PLOS Genetics (2013)
Down-regulation of BRCA1 Expression by miR-146a and miR-146b-5p in Triple Negative Sporadic Breast Cancers
Amandine I Garcia;Monique Buisson;Pascale Bertrand;Ruth Rimokh.
Embo Molecular Medicine (2011)
Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study
Susan L. Neuhausen;Sylvie Mazoyer;Lori Friedman;Michael Stratton.
American Journal of Human Genetics (1998)
The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons
Laure Perrin-Vidoz;Olga M. Sinilnikova;Dominique Stoppa-Lyonnet;Gilbert M. Lenoir.
Human Molecular Genetics (2002)
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer
Catherine M Phelan;Karoline B Kuchenbaecker;Karoline B Kuchenbaecker;Jonathan P Tyrer;Siddhartha P Kar.
Nature Genetics (2017)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Institute Curie
University of Toronto
QIMR Berghofer Medical Research Institute
University of Trieste
Mayo Clinic
University of Pennsylvania
University of Pennsylvania
University of Cambridge
University of Utah
Fondazione IRCCS Istituto Nazionale dei Tumori
Northeastern University
University of Nottingham
University of Montreal
University of Hohenheim
University of Newcastle Australia
University of Cologne
University College Cork
University of Maryland, Baltimore
University of Massachusetts Medical School
Centers for Disease Control and Prevention
University of Strasbourg
Boise State University
Metropolitan Water District of Southern California
University of Otago
The Ohio State University
South African Medical Research Council